CL2017002967A1 - Beta-caseinas a2 y capacidad antioxidante. - Google Patents

Beta-caseinas a2 y capacidad antioxidante.

Info

Publication number
CL2017002967A1
CL2017002967A1 CL2017002967A CL2017002967A CL2017002967A1 CL 2017002967 A1 CL2017002967 A1 CL 2017002967A1 CL 2017002967 A CL2017002967 A CL 2017002967A CL 2017002967 A CL2017002967 A CL 2017002967A CL 2017002967 A1 CL2017002967 A1 CL 2017002967A1
Authority
CL
Chile
Prior art keywords
antioxidant capacity
beta
caseins
caseina
dispositioning
Prior art date
Application number
CL2017002967A
Other languages
English (en)
Inventor
Andrew John Clarke
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57394138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002967(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of CL2017002967A1 publication Critical patent/CL2017002967A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)

Abstract

<p>METODO PARA MEJORAR LA CAPACIDAD ANTIOXIDANTE EN UN ANIMAL PROPORCIONANDOLE UNA COMPOSICION QUE CONTIENE BETA-CASEINA A2 QUE EVITA O REDUCE EL RIESGO DE ENFERMEDADES O TRASTORNOS ASOCIADOS CON EL ESTRES OXIDATIVO Y LOS EFECTOS DEL ENVEJECIMIENTO, Y PROMUEVE LA RECUPERACION DEL TEJIDO DESPUES DEL EJERCICIO FISICO Y LA FERTILIDAD.</p>
CL2017002967A 2015-05-22 2017-11-22 Beta-caseinas a2 y capacidad antioxidante. CL2017002967A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562165854P 2015-05-22 2015-05-22

Publications (1)

Publication Number Publication Date
CL2017002967A1 true CL2017002967A1 (es) 2018-06-01

Family

ID=57394138

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002967A CL2017002967A1 (es) 2015-05-22 2017-11-22 Beta-caseinas a2 y capacidad antioxidante.

Country Status (17)

Country Link
US (1) US10702580B2 (es)
EP (1) EP3297643A4 (es)
JP (1) JP7137745B2 (es)
KR (1) KR102374024B1 (es)
CN (2) CN122398856A (es)
AU (2) AU2016267960B2 (es)
BR (1) BR112017024975B1 (es)
CA (1) CA2986889C (es)
CL (1) CL2017002967A1 (es)
HK (1) HK1250631A1 (es)
IL (1) IL255725B (es)
MX (1) MX392728B (es)
MY (1) MY190600A (es)
PH (1) PH12017550132A1 (es)
RU (1) RU2751945C9 (es)
WO (1) WO2016190750A1 (es)
ZA (1) ZA201707968B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746167A (en) 2016-03-30 2023-04-28 A2 Milk Co Ltd Beta-caseins and cognitive function
WO2018063008A1 (en) * 2016-09-30 2018-04-05 The A2 Milk Company Limited Beta-caseins and gut microbiota
CN115553340A (zh) * 2022-10-18 2023-01-03 北大荒完达山乳业股份有限公司 一种具有提高免疫力功能的降敏牛奶及其制备方法
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
CN121606084B (zh) * 2026-02-03 2026-04-17 内蒙古伊利实业集团股份有限公司 一种有助于预防和/或改善缺铁性贫血的组合物、食品及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
RU2157233C1 (ru) * 1999-05-11 2000-10-10 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
WO2002019832A1 (en) 2000-09-08 2002-03-14 New Zealand Dairy Board MILK CONTAINING β-CASEIN WITH PROLINE AT POSITION 67 DOES NOT AGGRAVATE NEUROLOGICAL DISORDERS
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
RU2280448C2 (ru) * 2002-11-10 2006-07-27 Институт биофизики клетки РАН Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих
MXPA06009529A (es) * 2004-02-23 2007-04-10 Texas A & M Univ Sys Composiciones antioxidantes y metodos para el uso de las mismas.
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
EP2448958A4 (en) * 2009-06-01 2013-11-06 Kenneth James Friel HUMAN MILK PEPTIDES
EP2822568B1 (en) * 2012-03-09 2020-06-17 Fonterra Co-Operative Group Limited Uses of casein compositions
WO2014194292A1 (en) * 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
RU2671562C2 (ru) 2013-07-12 2018-11-02 Зэ А2 Милк Компани Лимитед Бета-казеин а2 и уменьшение или предотвращение симптомов непереносимости лактозы
CN105555295A (zh) * 2013-08-23 2016-05-04 艾尔牛奶有限公司 β-酪蛋白A2和血葡萄糖水平

Also Published As

Publication number Publication date
RU2017142002A (ru) 2019-06-24
IL255725B (en) 2021-10-31
MX2017014991A (es) 2018-04-10
RU2751945C2 (ru) 2021-07-21
NZ737716A (en) 2024-11-29
US20180169186A1 (en) 2018-06-21
BR112017024975B1 (pt) 2022-03-15
KR20180010251A (ko) 2018-01-30
CA2986889A1 (en) 2016-12-01
EP3297643A4 (en) 2019-02-06
PH12017550132A1 (en) 2018-05-07
CN107708711A (zh) 2018-02-16
RU2017142002A3 (es) 2019-11-21
BR112017024975A2 (pt) 2018-08-07
CA2986889C (en) 2023-08-29
AU2016267960B2 (en) 2022-04-07
HK1250631A1 (zh) 2019-01-11
AU2016267960A1 (en) 2017-12-14
US10702580B2 (en) 2020-07-07
RU2751945C9 (ru) 2021-12-21
MX392728B (es) 2025-03-24
IL255725A (en) 2018-01-31
CN122398856A (zh) 2026-07-17
ZA201707968B (en) 2019-10-30
JP2018514236A (ja) 2018-06-07
WO2016190750A1 (en) 2016-12-01
MY190600A (en) 2022-04-27
AU2022204759A1 (en) 2022-07-28
JP7137745B2 (ja) 2022-09-15
KR102374024B1 (ko) 2022-03-11
EP3297643A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018000897A1 (es) Composicion de fortalecimiento del cabello y metodo para fortalecer el cabello.
CL2017003089A1 (es) Formas de dosificación sólidas de palbociclib
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CL2017002728A1 (es) Método para el tratamiento de cáncer
MX2018005745A (es) Control de niveles redox celulares.
MX2016014102A (es) Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
MX2018005165A (es) Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
MX2017014375A (es) Moduladores del ccr2.
UY37098A (es) Moduladores de ror-gamma
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
UY37351A (es) Complemento para el pienso
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
CU20170099A7 (es) Terapias de combinación para el tratamiento de cánceres